Modern times call for modernized treatment strategies for advanced gastrointestinal stromal tumors.
作者信息
Perati Shruthi R, Blakely Andrew M
机构信息
Surgical Oncology Program, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA.
出版信息
J Gastrointest Oncol. 2024 Aug 31;15(4):2013-2015. doi: 10.21037/jgo-24-501. Epub 2024 Aug 17.
Abstract
摘要
相似文献
1
Modern times call for modernized treatment strategies for advanced gastrointestinal stromal tumors.现代社会需要针对晚期胃肠道间质瘤的现代化治疗策略。
J Gastrointest Oncol. 2024 Aug 31;15(4):2013-2015. doi: 10.21037/jgo-24-501. Epub 2024 Aug 17.
2
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.瑞派替尼对比舒尼替尼用于伊马替尼治疗后进展的晚期胃肠道间质瘤患者：Ⅲ期 INTRIGUE 试验的通俗易懂总结。
Future Oncol. 2023 Nov;19(36):2383-2393. doi: 10.2217/fon-2022-1191. Epub 2023 Aug 18.
3
Ripretinib for the treatment of advanced gastrointestinal stromal tumor.瑞派替尼用于治疗晚期胃肠道间质瘤。
Therap Adv Gastroenterol. 2021 Apr 15;14:17562848211008177. doi: 10.1177/17562848211008177. eCollection 2021.
4
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.瑞派替尼对比舒尼替尼用于伊马替尼治疗后进展的晚期胃肠间质瘤患者（INTRIGUE）：一项随机、开放标签、III 期临床试验。
J Clin Oncol. 2022 Dec 1;40(34):3918-3928. doi: 10.1200/JCO.22.00294. Epub 2022 Aug 10.
5
The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.伊马替尼耐药胃肠间质瘤（GIST）背后的多方面景观：来自 ripretinib 的启示。
Pharmacol Ther. 2023 Aug;248:108475. doi: 10.1016/j.pharmthera.2023.108475. Epub 2023 Jun 10.
6
Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.瑞派替尼治疗反复复发的直肠胃肠道间质瘤：一例报告。
Ann Palliat Med. 2021 Apr;10(4):4994-4998. doi: 10.21037/apm-21-722.
7
Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.瑞派替尼联合酪氨酸激酶抑制剂作为难治性胃肠道间质瘤的晚期治疗选择：两例病例报告及文献综述
Front Pharmacol. 2023 May 23;14:1122885. doi: 10.3389/fphar.2023.1122885. eCollection 2023.
8
Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.伊马替尼治疗失败后一线药物治疗晚期胃肠道间质瘤的疗效：一项网络荟萃分析。
Cancer Med. 2023 Jun;12(11):12187-12197. doi: 10.1002/cam4.5912. Epub 2023 Apr 21.
9
Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.瑞派替尼治疗胃肠道间质瘤安全性和有效性的新数据
Clin Exp Gastroenterol. 2023 Feb 10;16:11-19. doi: 10.2147/CEG.S351839. eCollection 2023.
10
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.第二代酪氨酸激酶抑制剂治疗伊马替尼耐药胃肠道间质瘤的临床疗效：近期临床试验的荟萃分析
Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.
引用本文的文献
1
Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies.琥珀酸脱氢酶缺陷型胃肠道间质瘤全身治疗的最新进展
Curr Treat Options Oncol. 2025 Apr;26(4):227-240. doi: 10.1007/s11864-025-01304-w. Epub 2025 Mar 6.
本文引用的文献
1
Survival outcomes and prognostic factors of advanced gastrointestinal stromal tumors: in the era of multiple tyrosine kinase inhibitors.晚期胃肠道间质瘤的生存结局及预后因素：在多靶点酪氨酸激酶抑制剂时代
J Gastrointest Oncol. 2024 Jun 30;15(3):931-945. doi: 10.21037/jgo-24-63. Epub 2024 Jun 27.
2
Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.瑞派替尼治疗胃肠道间质瘤安全性和有效性的新数据
Clin Exp Gastroenterol. 2023 Feb 10;16:11-19. doi: 10.2147/CEG.S351839. eCollection 2023.
3
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.胃肠道间质瘤的全身治疗：当前标准与新挑战
Curr Treat Options Oncol. 2022 Sep;23(9):1303-1319. doi: 10.1007/s11864-022-00996-8. Epub 2022 Aug 17.
4
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.瑞派替尼对比舒尼替尼用于伊马替尼治疗后进展的晚期胃肠间质瘤患者（INTRIGUE）：一项随机、开放标签、III 期临床试验。
J Clin Oncol. 2022 Dec 1;40(34):3918-3928. doi: 10.1200/JCO.22.00294. Epub 2022 Aug 10.
5
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.阿伐普利尼治疗晚期 PDGFRA D842V 突变胃肠间质瘤（NAVIGATOR）：一项多中心、开放标签、1 期临床试验。
Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2.
6
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.酪氨酸激酶抑制剂对伊马替尼耐药胃肠间质瘤继发 kit 突变的互补作用。
Br J Cancer. 2019 Mar;120(6):612-620. doi: 10.1038/s41416-019-0389-6. Epub 2019 Feb 22.
7
Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.酪氨酸激酶抑制剂治疗转移性胃肠道间质瘤的细胞减灭术：2 家机构的分析。
Ann Surg. 2018 Aug;268(2):296-302. doi: 10.1097/SLA.0000000000002281.
Zotero 插件